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Objective/Background: Pyrazinamide (PZA) is an antibacterial used in the first-line regimen
against tuberculosis (TB) for its action against dormant bacilli. PZA is also included in
the new short regimen to treat multidrug-resistant TB (MDR-TB). However, the prevalence
and significance of PZA resistance is not known in Central and West Africa.
Methods: Between 2013 and 2016, we collected samples from MDR-TB patients recruited in
an observational study implementing the new short MDR-TB regimen in six countries:
Burundi (n = 35), Cameroon (n = 135), Niger (n = 57), Central African Republic (n = 35),
Democratic Republic of the Congo (n = 99), and Rwanda (n = 16). Resistance to rifamipicine,
isoniazide, injectables, and fluoroquinolones was tested by phenotypic (live strains) or
genotypic methods (inactivated strains). Resistance to PZAwas analyzed through sequenc-
ing of the pncA gene. Relevance of mutations was established based on recent literature.
Results: From 377 patients with MDR-TB, 354 (94%) samples were successfully sequenced.
Among those, 53% (189) presented a mutation in pncA that confers a reported (121), poten-
tial (56), or unclear (12) resistance. Furthermore, six isolates presented a mutation associ-
ated with PZA sensitivity. The frequency of resistance per country was 26% in Central
African Republic, 39% in Niger, 49% in Cameroon, 66% in Burundi, 68% in Democratic
Republic of the Congo, and 87% in Rwanda. Isolates presented 109 different profiles of
mutations, including 73 occurring only once. Codon 12 was most frequently affected
(15 isolates), including 10 isolates with Asp12Ala. These 10 isolates came from three differ-
ent countries, and presented different profiles of resistance to other drugs. The two next
most frequent mutations, Met175Ile and Gln10Pro (8 isolates and 7 isolates, respectively),
each suggest clusters of transmission, with similar geographical and resistance
characteristics. Moreover, four isolates presented two simultaneous genetic variations,
and 11 patients had a mix of sensitive and resistant bacilli. Preliminary data tend to indi-
cate that patients carrying a PZA-resistant isolate had a higher failure rate on the new short
MDR-TB treatment regimen (7% vs. 3%). All isolates resistant to injectables (4) and most
(19/21) of those resistant to fluoroquinolones, including two extremely-resistant TB
isolates, were also resistant to PZA.Antwerp,
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concomitant resistance to pyrazinamide. Int. J.Conclusion: Similar to other regions in the world, the majority of MDR-TB strains from Sub-
Saharan Africa countries are resistant to PZA, albeit with diverse rates between countries.
We identified a diverse range of mutations in pncA, with 30% of them not previously
reported. The impact of such resistance on the success of the short MDR-TB regimen will
require more investigation.Conflicts of interest
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